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Abstract
There is growing interest in the potential neuroprotective
properties of gelsolin. In particular, plasma-type gelsolin
(pGSN) can ameliorate deleterious inflammatory
response by scavenging pro-inflammatory signals such
as actin and lipopolysaccharide. In a recent issue of
Critical Care, Pan and colleagues report an important
association between pGSN and subarachnoid
hemorrhage (SAH) disease severity, and found pGSN
to be a novel and promising biomarker for SAH clinical
outcome. Previous research shows pGSN may be
actively degraded by neurovascular proteases such as
matrix metalloproteinases in the cerebral spinal fluid of
SAH patients. Taken together, these results suggest that
pGSN is not only a novel marker of SAH clinical outcome,
but may also play an active mechanistic role in SAH, and
potentially serve as a future therapeutic target.
In a recent issue of Critical Care, Pan and colleagues [1]
report the largest study to date on blood plasma-type
gelsolin (pGSN) as a promising biomarker in subarach-
noid hemorrhage (SAH). In a cohort of 262 well charac-
terized SAH patients and 150 control subjects, Pan and
colleagues found that low blood pGSN (compared to
healthy controls) is independently predictive of poor
outcome or death [1]. A pGSN level <63.3 mg/L has
80.8% sensitivity and 75.1% specificity in predicting poor
neurologic outcome at 6 months. They also found an
important association between the level of gelsolin and
severity of SAH, as measured by World Federation of
Neurosurgical Societies and Fisher grading scales [1].
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There is growing interest in the potential neuroprotec-
tive properties of gelsolin, which has two distinct isoforms.
Cytoplasmic gelsolin (cGSN) is intracellular and ubiqui-
tously expressed by all tissues, while pGSN has a 23 amino
acid moiety targeted for extracellular secretion [2,3].
Though cGSN has been implicated in numerous biological
processes, including cell motility, apoptosis, and phagocyt-
osis [4], the function of pGSN remains largely unknown.
Since pGSN can scavenge circulating actin and lipopoly-
saccharide, it is thought that pGSN may dampen the dele-
terious pro-inflammatory effects of these circulating
inflammatory mediators [4].
Animal data have suggested a neuroprotective role for
gelsolin since gelsolin-null neurons enhance cell death
and gelsolin-null mice have larger infarct sizes following
ischemia [5]. Gelsolin-null cells and animals are deficient
in both cGSN and pGSN. Subsequent experiments
showed that local infusion of pGSN decreases infarct
size after ischemia [6], suggesting pGSN has a pivotal
role in stroke.
Human data have consistently shown that pGSN is de-
creased in severe illnesses, including sepsis [7], and that
lower blood pGSN is associated with higher mortality [8].
In neurovascular disorders, pGSN is decreased in both
blood and cerebral spinal fluid (CSF) in SAH [9], and de-
creased blood pGSN is independently associated with
mortality after intracerebral hemorrhage and ischemic
stroke [10,11]. However, the fact that pGSN is associated
with a wide spectrum of illnesses raises the concern that
blood pGSN depletion is a non-specific marker of disease
severity.
Is there any evidence that pGSN may be mechanistic-
ally involved in SAH? Indeed, SAH is the only condition
where pGSN has been identified in the CSF compart-
ment itself [9]. In SAH, novel degraded pGSN fragments
were also identified in the CSF - likely resulting from
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[9], the elevation of which is associated with worse SAH
outcome [12].
In their study, Pan and colleagues very nicely demon-
strated a dose-dependent effect of pGSN on SAH disease
severity - the lower the level of pGSN, the more severe
the SAH grade and the worse the clinical outcome [1].
Previous research has shown pGSN to be present in the
CSF compartment in SAH and that MMPs may mediate
the depletion of pGSN [9,12]. Taken together, these
studies suggest that, in the case of SAH, pGSN may be
more than just a non-specific marker. It may play an ac-
tive mechanistic role in SAH, and could potentially serve
as a therapeutic target.
Many questions still remain in the gelsolin story in
SAH. Exactly how does blood pGSN affect SAH out-
come? Where is the source of pGSN in the CSF - does it
come from blood? How does the pGSN-MMP pathway
facilitate inflammation and injury in the central nervous
system and blood? Further targeted mechanistic studies
and collaborative multicenter translational and clinical
studies are needed to answer these important questions.
Indeed, pGSN may not only be a novel and important
clinical biomarker for SAH clinical outcome, but may
also be a future potential target for treatment.
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